Most Read Articles
Pearl Toh, 4 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.

Hydroxychloroquine reduces MACE risk in patients with lupus erythematosus

05 Apr 2021

Use of hydroxychloroquine (HCQ) is inversely associated with the risk of cardiovascular events in patients with lupus erythematosus (LE), as indicated by the results of a recent study.

This observational cohort study used Danish nationwide registers to determine whether HCQ treatment correlated with major adverse cardiovascular events (MACE; ie, myocardial infarction, ischaemic stroke, or cardiovascular-associated death) in patients with first-time diagnosis of cutaneous or systemic LE between 1997 and 2017.

Cox regression models were used to calculate the hazard ratio (HR) for the risk of MACE and to compare time on and off HCQ, including never users. The authors adjusted the models for age, sex, socioeconomic status, concomitant treatment, and cardiovascular risk factors.

A total of 4,587 patients with LE were identified, of whom 2,343 (51 percent) were treated with HCQ during the study period. An inverse association was observed between use of HCQ and MACE risk among patients with systemic LE (adjusted HR, 0.65, 95 percent confidence interval [CI], 0.46–0.90) and those with cutaneous LE (adjusted HR, 0.71, 95 percent CI, 0.42–1.19).

Sensitivity analyses including a case-time control design revealed consistent results.

“Our findings indicate an opportunity to reduce the risk of cardiovascular events in patients with LE through use of HCQ,” the authors said.

One limitation of this study was the lack of information on disease activity or severity.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.